India, Nov. 3 -- Pfizer Inc. (PFE) reported third-quarter 2026 results, with growth in its non-COVID portfolio and launched and acquired products, and raised its full-year revenue and adjusted earnings guidance.
Company Profile
Pfizer is a global biopharmaceutical company developing and commercializing medicines and vaccines across oncology, immunology, internal medicine, rare diseases and other therapeutic areas.
Q3 Financial Highlights
Third-quarter 2026 revenue totaled $16.6 billion, remaining broadly unchanged from the same period last year on an operational basis.
The company reported its net income of $3.24 billion or $0.56 per share, compared with $3.54 billion or $0.62 per share in the same period last year.
Excluding contribu...